Drug-Induced Interstitial Lung Disease From PARP Inhibitors (Olaparib and Niraparib) for Ovarian Cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (olaparib and niraparib) for ovarian cancer. B...
Saved in:
| Main Authors: | Hiroshi Sugimoto, Takanori Enomoto, Mamoru Okuno, Naoko Chayahara, Hiroki Morita, Kyosuke Nakata |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2023-03-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2022.0711 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China
by: Dengfeng Wang, et al.
Published: (2025-05-01) -
Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance
by: Desirèe Speranza, et al.
Published: (2025-04-01) -
Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant <i>BRCA1</i>-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge
by: Chi-Ting Shih, et al.
Published: (2024-11-01) -
PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer
by: Jayson Cagadas Pasaol, et al.
Published: (2025-07-01) -
Development and evaluation of a 99mTc-labeled olaparib analog for PARP imaging
by: Wei Xu, et al.
Published: (2025-07-01)